EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›AXGN

AXGN

Axogen, Inc.

Next earnings Aug 3, 2026 · consensus $0.13 EPS, $68.3M rev

Last earnings +6.6% on 2026-04-28

Hold
$44.93
▲ +0.99%
$44.93▲ +358.94%
over 1Y
L $9.79EODHDH $44.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.0%
1W-0.0%
1M+12.7%
3M+43.6%
YTD+44.9%
1Y+358.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
D
Valuation
Fair value
Filings
Watch
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Buy

Revenue grew 20.2% YoY; but unprofitable (net margin -7.0%).

Revenue (FY2025) $225M · FY2025

Axogen, Inc. shows $225M in FY2025 revenue (+20.2% YoY), a -7.0% net margin, and -12.2% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$127M$139M$159M$187M$225M
Gross profit$104M$109M$122M$142M$167M
Operating income-$25.4M-$29.7M-$21.5M-$3.29M-$7.85M
Net income-$27.0M-$28.9M-$21.7M-$9.96M-$15.7M
Diluted EPS-$0.65-$0.69-$0.51-$0.23-$0.34
Net margin-21.2%-20.9%-13.7%-5.3%-7.0%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$2.35B
EV / EBITDA—
EV / Sales10.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-0.7%
FCF yield-0.1%

Quality & risk

ROIC (est.)-3.5%
Free cash flow-$2.93M
Total debt$50.1M
Net cash-$14.6M
Altman Z-Score14.55 safe
Piotroski F-Score5/9

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+17.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-06-23
  2. DEF 14A Proxy statement2026-04-29
  3. 8-K Earnings results2026-04-28
  4. 10-Q Quarterly report2026-04-28
  5. 8-K Earnings results2026-02-24
  6. 10-K Annual report2026-02-24
  7. 8-K Material agreement2026-01-23
  8. 8-K Earnings results2026-01-12
  9. 8-K Officer / director change2025-12-05

Recent filings

all on EDGAR ↗
4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗8-KPeriod ending 2026-06-232026-06-23open ↗4Period ending 2026-06-192026-06-23open ↗4Period ending 2026-06-192026-06-23open ↗4Period ending 2026-06-192026-06-23open ↗4Period ending 2026-06-192026-06-23open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueF
GrowthC-
ProfitabilityF
Financial healthC+
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$225M
+20.2% YoY
Net margin
-7.0%
ROE
-12.2%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$225M+20.2%
Net income-$15.7M-57.6%
Gross profit$167M+17.9%
Operating income-$7.85M-138.8%
Diluted EPS-$0.34-47.8%
Cash & equivalents$35.5M+29.0%
Total assets$222M+8.8%
Total liabilities$92.8M-7.0%
Stockholders' equity$129M+24.0%
Gross: 74.3%Op.: -3.5%L/E: 0.72x

Frequently asked

Is Axogen, Inc. (AXGN) a buy?
AXGN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 20.2% YoY; but unprofitable (net margin -7.0%).
What is Axogen, Inc.'s quality score?
AXGN scores 42.29411764705882/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000805928, latest 10-Q filed 2026-04-28) · EODHD · as of 6/26/2026, 6:16:14 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-19
Levine Alan M
Director
Exercise14.2K

Dividends

Irregular
Yield (TTM)
—
Annual / share
—
Last ex-date
2010-01-27
Last amount
$1.00
ex 2010-01-27paid 2010-02-12$1.00
ex 2005-02-23paid 2005-03-11$0.06
ex 1992-07-10$0.04

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-04-28Miss -4.5% est▲ +6.60%8-K ↗
2026-02-24Miss -29.4% est▼ -8.14%8-K ↗
2026-01-12Miss -29.4% est▼ -5.85%8-K ↗
2025-10-29Beat +64.2% est▲ +23.06%8-K ↗
2025-08-05Beat +85.8% est▲ +9.32%8-K ↗
2025-05-08—▼ -23.18%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Dow Jones AI Giant Nvidia Stock Tumbles To Key Support Level Amid Market Sell-OffBullish
finance.yahoo.com· 2026-06-09
Eli Lilly Leads Medical Stocks To Watch, While Google Finds SupportBullish
finance.yahoo.com· 2026-06-06
The Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfBullish
globenewswire.com· 2026-05-22
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather SteamBullish
finance.yahoo.com· 2026-05-14
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare ConferenceBullish
globenewswire.com· 2026-04-30
Sector Update: Health Care Stocks Edge Higher Late AfternoonBullish
finance.yahoo.com· 2026-04-28

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score42 vs 67
Revenue growth20.2% vs 7.1%
Net margin-7.0% vs 10.5%
Return on equity-12.2% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 5d
Bearish
-0.05
vs typical · 5 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.